A promising new chapter for PI3Kδ inhibition: Nature Communications publications reveal novel mechanism behind iOnctura’s roginolisib

/in

• First publication reveals how roginolisib uniquely locks the cancer-driving enzyme PI3Kδ in an inactive state, differentiating the drug from other PI3Kδ inhibitors • Second publication outlines first-in-human (FiH) study results, demonstrating roginolisib’s favorable tolerability profile and encouraging clinical findings in patients with cancer, including metastatic uveal melanoma (mUM) • Publication of the peer-reviewed papers […]

Read more

BIO-Europe C-Suite Survey: Biopharma dealmaking set to accelerate, but investor caution still caps ambition

/in

75% of biopharma leaders expect partnering and M&A appetite to increase over the next 12 months, none expect a decline 69% expect access to capital to improve, yet 79% identify investor risk aversion as the biggest constraint on biotech investment 52% say US policy uncertainty has made Europe more attractive to build and partner in, […]

Read more

Resolution Therapeutics to present interim Phase I/II EMERALD study data on RTX001 as a late-breaker at AASLD 2026

/in

Interim data from Phase I/II EMERALD study for RTX001, Resolution’s engineered Regenerative Macrophage Therapy, accepted as late-breaking presentation Dr. Lara Campana to present preclinical data on intravenous Regenerative Macrophage Therapy for decompensated cirrhosis Edinburgh and London, UK, 6 October 2026 – Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company pioneering Regenerative Macrophage Therapy […]

Read more

RougeTx Launches with $58 Million Series A Financing to Advance First-in-Class Treatment for Hereditary Hemorrhagic Telangiectasia

/in

  Series A co-led by BioGeneration Ventures, Angelini Ventures and Kurma Partners, with participation from Epidarex Capital, Vesalius Biocapital Partners, ROM Utrecht Region, p53 Invest and Kerna Ventures. Financing will advance a potential once-daily oral treatment designed to restore blood vessel stability in HHT, a serious inherited bleeding disorder with no approved therapies. periSCOPE platform […]

Read more

Poolbeg Pharma – Cancer Immunotherapy-Induced CRS Patent Granted in South Korea

/in

Patent grant further strengthens POLB 001’s global intellectual property portfolio 6 October 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that a South Korean patent relating to POLB 001 has been formally granted. The patent, entitled “Medicinal products and methods for […]

Read more
© Optimum Strategic Communications.